Never looked at CYDY until today. So I took a gander thru my old, retired eyes of a day trader. Didn’t realize it was an OTCer. From what I saw (on their website), CYDY is a “one trick pony” with Leronlimab. While Leronlimab does have the original HIV application, that is only in Phase 2b. The spike to above $1 was solely for the Covid application with hope of a EUA. The fact that there is now a delay of 2-3 weeks caused by the U.S. FDA, MHRA and Health Canada, with a possible negative outcome, that has made and will continue to make investors nervous (as seen by the pps today). Regardless of the viability of Leronlimab (still a go for HIV, etc.), if use for Covid is ruled out, the pps will probably return to what it was March 2020. Those who will stay are the ones who invested because of the HIV application.
Generex Biotechnology Corp. (GNBT) Stock Research Links